IMS 2022 | Mass spectrometry, NGS & NGF for MRD detection in multiple myeloma
Meral Beksac
• 25 Aug 2022
Meral Beksac, MD, Ankara University, Ankara, Turkey, comments on the use of measurable residual disease (MRD) detection techniques including next-generation sequencing (NGS), next-generation flow cytometry (NGF), and mass spectrometry (MS), highlighting some of the advantages of these techniques. Dr Beksac explains that MS is a blood-based MRD assay that can be used in addition to NGS or NGF when a patient is MRD-positive.This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
